Recent data found that diverticular disease (DD) of the colon shows similarities with inflammatory bowel diseases (IBD). In particular, the detection of microscopic inflammation and the clinical response to mesalazine seem to confirm the hypothesis that inflammation may be a key point for the appearance of symptoms and development of complications. In light of this hypothesis, several studies have recently focused their attention on the role of biomarkers in predicting and monitoring the course of the disease. C-reactive protein (CRP), white blood cell count, erythrocyte sedimentation rate, and fecal calprotectin (FC) have therefore been investigated. As in IBD, CRP seems to be the most effective marker of histological and clinical severity of the disease. In particular, CRP below 50 mg/l suggests an acute uncomplicated diverticulitis (AUD), whereas CRP higher than 200 mg/l is a strong indicator of DD complicated by perforation. As in IBD, FC seems to be a noninvasive sensitive marker of DD severity. In particular, FC may show slight increased valued already in symptomatic uncomplicated DD (SUDD) (FC value ≥15 µg/ml seems to be predictive of SUDD). As expected, FC shows higher values in AUD (FC value ≥60 µg/ml seems to be predictive of AUD). Finally, FC seems to be useful also in monitoring the therapeutic response in DD. In fact, FC values decreased significantly in patients responding to therapy, whereas they persisted to increase in patients who failed to obtain remission.

Keywords:
Biomarkers, C-reactive protein, Erythrocyte sedimentation rate, Fecal calprotectin
1.
Jun S, Stollman N: Epidemiology of diverticular disease. Best Pract Res Clin Gastroenterol 2002;16:529–542.
2.
Tursi A, Papagrigoriadis S: Review article: the current and evolving treatment of colonic diverticular disease. Aliment Pharmacol Ther 2009;30:532–546.
3.
Narayan R, Floch MH: Microscopic colitis as part of the natural history of diverticular disease (abstract). Am J Gastroenterol 2002;97(suppl):112.
4.
Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Danese S, Aiello F: Assessment and grading of mucosal inflammation in colonic diverticular disease. J Clin Gastroenterol 2008;42:699–703.
5.
Cianci R, Iacopini F, Petruzziello L, Cammarota G, Pandolfi F, Costamagna G: Involvement of central immunity in uncomplicated diverticular disease. Scand J Gastroenterol 2009;44:108–115.
6.
Pereira JM, Sirlin CB, Pinto PS, Jeffrey RB, Stella DL, Casola G: Disproportionate fat stranding: a helpful CT sign in patients with acute abdominal pain. Radiographics 2004;24:703–715.
7.
Tursi A, Brandimarte G, Giorgetti G, Elisei W, Maiorano M, Aiello F: The clinical picture of uncomplicated versus complicated diverticulitis of the colon. Dig Dis Sci 2008;53:2474–2479.
8.
Tursi A, Elisei W, Giorgetti GM, Aiello F, Brandimarte G: Inflammatory manifestations at colonoscopy in patients with colonic diverticular disease. Aliment Pharmacol Ther 2011;33:358–365.
9.
Baumann BM, Chen EH, Mills AM, Glaspey L, Thompson NM, Jones MK, Farner MC: Patient perceptions of computed tomographic imaging and their understanding of radiation risk and exposure. Ann Emerg Med 2011;58:1–7.
10.
Winter DC: Commentary: Perspectives on diverticulitis and the art of clinical science – treat the man not the scan. Colorectal Dis 2010;12:186–187.
11.
Hale WB, NDSG: Colonoscopy in the diagnosis and management of diverticular disease. J Clin Gastroenterol 2008;42:1142–1144.
12.
Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89–95.
13.
Desai D, Faubion WA, Sandborn WJ: Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007;25:247–255.
14.
Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ: Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707–712.
15.
Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I: Use of surrogate markers of inflammation and Rome criteria to distinguish organic from non-organic intestinal disease. Gastroenterology 2002;123:450–460.
16.
Köhler L, Sauerland S, Neugebauer E, Scientific Committee of the European Association for Endoscopic Surgery (EAES): Diagnosis and treatment of diverticular disease. Results of a Consensus Development Conference. Surg Endosc 1999;13:430–436.
17.
Laméris W, van Randen A, van Gulik TM, Busch OR, Winkelhagen J, Bossuyt PM, Stoker J, Boermeester MA: A clinical decision rule to establish the diagnosis of acute diverticulitis at the emergency department. Dis Colon Rectum 2010;53:896–904.
18.
Andeweg CS, Knobben L, Hendriks JC, Bleichrodt RP, van Goor H: How to diagnose acute left-sided colonic diverticulitis: proposal for a clinical scoring system. Ann Surg 2011;253:940–946.
19.
Tursi A, Elisei W, Brandimarte G, Giorgetti GM, Aiello F: Predictive value of serologic markers of degree of histologic damage in acute uncomplicated colonic diverticulitis. J Clin Gastroenterol 2010;44:702–706.
20.
Käser SA, Fankhauser G, Glauser PM, Toia D, Maurer CA: Diagnostic value of inflammation markers in predicting perforation in acute sigmoid diverticulitis. World J Surg 2010;34:2717–2722.
21.
Ridgway PF, Latif A, Shabbir J, Ofriokuma F, Hurley MJ, Evoy D, O’Mahony JB, Mealy K: Randomized controlled trial of oral vs. intravenous therapy for the clinically diagnosed acute uncomplicated diverticulitis. Colorectal Dis 2009;11:941–946.
22.
Hall JF, Roberts PL, Ricciardi R, Read T, Scheirey C, Wald C, Marcello PW, Schoetz DJ: Long-term follow-up after an initial episode of diverticulitis: what are the predictors of recurrence? Dis Colon Rectum 2011;54:283–288.
23.
Etzioni DA, Chiu VY, Cannom RR, Burchette RJ, Haigh PI, Abbas MA: Outpatient treatment of acute diverticulitis: rates and predictors of failure. Dis Colon Rectum 2010;53:861–865.
24.
Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, Sterpi C, Marchi S, Maltinti G: Role of faecal calprotectin as a non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642–647.
25.
Tibble J, Teahon K, Thjodleifssan B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M, Bjarnason I: A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 2000;47:506–513.
26.
Pezzilli R, Barrassi A, Morselli Labate AM, Tinozzi S, Fantini I, Gizzi G, Latzniker M, Villani V, Melzi D’Eril G, Corinaldesi R: Fecal calprotectin levels in patients with colonic polyposis. Dig Dis Sci 2008;53:47–51.
27.
Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F: Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis 2009;24:49–55.
28.
Vestergaard TA, Nielsen SL, Dahlerup JF, Hornung N: Fecal calprotectin: assessment of a rapid test. Scand J Clin Lab Invest 2007;i:1–5.
29.
Dumitru E, Alexandrescu L, Suceveanu AI, Dumitru IM, Tofolean IT: Fecal calprotectin in diagnosis of complicated colonic diverticular disease. Gastroenterology 2010;138(suppl 1):S365.
30.
Turkay C, Kasapoglu B: Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update. Clinics (Sao Paulo) 2010;65:221–231.
31.
Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason I: High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362–366.
32.
Johne B, Kronborg O, Tøn HI, Kristinsson J, Fuglerud P: A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 2001;36:291–296.
33.
Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA: Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197–250.
34.
Mimura T, Bateman AC, Lee RL, Johnson PA, McDonald PJ, Talbot IC, Kamm MA, MacDonald TT, Pender SL: Up-regulation of collagen and tissue inhibitors of matrix metalloproteinase in colonic diverticular disease. Dis Colon Rectum 2004;47:371–378.
35.
Klinge U, Rosch R, Junge K, Krones CJ, Stumpf M, Lynen-Jansen P, Mertens PR, Schumpelick V: Different matrix micro-environments in colon cancer and diverticular disease. Int J Colorectal Dis 2007;22:515–520.
36.
Rosemar A, Ivarsson ML, Börjesson L, Holmdahl L: Increased concentration of tissue-degrading matrix metalloproteinases and their inhibitor in complicated diverticular disease. Scand J Gastroenterol 2007;42:215–220.
37.
Mäkitalo L, Sipponen T, Kärkkäinen P, Kolho KL, Saarialho-Kere U: Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn’s disease after immunosuppressive treatment correlate with histological score and calprotectin values. Int J Colorectal Dis 2009;24:1157–1167.
38.
Gschossmann JM, Liebregts T, Adam B, Buenger L, Ruwe M, Gerken G, Holtmann G: Long-term effects of transient chemically induced colitis on the visceromotor response to mechanical colorectal distension. Dig Dis Sci 2004;49:96–101.
39.
Simpson J, Sundler F, Humes DJ, Jenkins D, Scholefield JH, Spiller RC: Post-inflammatory damage to the enteric nervous system in diverticular disease and its relationship to symptoms. Neurogastroenterol Motil 2009;21:e847–e858.
40.
Elli L, Roncoroni L, Bardella MT, Terrani C, Bonura A, Ciulla M, Marconi S, Piodi L: Absence of mucosal inflammation in uncomplicated diverticular disease. Dig Dis Sci 2011;56:2098–2103.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.